Enhancing the quality of life in visually impaired AMD patients

Article

An analysis of the AcrySof ReSTOR apodized diffractive intraocular lens

For many years we have induced pseudophakic myopia of 5 dioptres in our age-related macular degeneration (AMD) patients. This helped aid in near vision recovery and allowed patients to resume some activities in their lives that they were unable to previously do as a result of poor vision. It also avoided spectacle induced loss of contrast sensitivity. While our patients were pleased with their near acuity, they were displeased with the high myopic correction for distance acuity.

Low vision aid

While the lens is not indicated for this use, I realized that I could use the lens as a low vision aid. Under photopic conditions, a -2.00 distance refraction provides a near equivalent of +5.20 D with a best focus of 20 cm. The AcrySof ReSTOR lens technique does not reduce uncorrected distance acuity nearly as much as a -5.0 D myopia inducing monofocal lens. The patients were much happier now that they only needed a -2.0 D distance correction.

Our first two AMD patients that were implanted with the ReSTOR lens were absolutely ecstatic, so we started a pilot study. The pilot study was a prospective series of cataract patients with vision loss from AMD, who received an offlabel AcrySof ReSTOR IOL following phacoemulsification. Surgery was planned for a desired postoperative refraction of -2.0 to -3.0 spherical equivalent. This pilot study also demonstrated that not only was the patients' uncorrected near acuity improved, but also that many aspects of their quality of life improved; therefore a formal, multicentre study was conducted.

The 6-month multicentre included 20 eyes of 13 patients that were more than 50 years of age with stable, dry macular degeneration or with macular degeneration associated with disciform scarring per the doctor's examination. Near and distance Snellen visual acuities with and without correction were collected, as well as subjective patient quality of life statements collected pre and postoperatively. The National Eye Institute Visual Function Questionnaire (VFQ-25 Version 2000) was also administered to the patient's pre- and postoperatively.3

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.